Patents Examined by Anna P. Fagelson
  • Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
    Patent number: 4364935
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
    Patent number: 4364932
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human cytotoxic and suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 9, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
    Patent number: 4364922
    Abstract: A method of relieving atrioventricular conduction block by administering to a human or animal an effective amount of an adenosine antagonist that competitively inhibits adenosine or that reduces the level of adenosine present in myocardial tissue and associated fluids. A method of diagnosing atrioventricular conduction block caused by ischemia of the heart by measuring the time delay between atrial and ventricular excitation before and after the administration of an adenosine antagonist. Specific antagonists disclosed include methylxanthines.
    Type: Grant
    Filed: October 14, 1980
    Date of Patent: December 21, 1982
    Assignee: University of Virginia Alumni Patents Foundation
    Inventors: Robert M. Berne, Luiz Belardinelli, Rafael Rubio
  • Production of immunogenic products and treatment of allergic reactions therewith
    Patent number: 4364938
    Abstract: A method for the production of immunogenic products useful in the therapeutic treatment of allergic conditions in patients, comprising the solvent extraction from allergenic substances of the solvent soluble components thereof to obtain the residue of extraction which may be employed as an immunogenic material possessing reduced allergenicity. If desired, the thus obtained residue of extraction may be further treated with a suitable ketone, aldehyde, lactone or epoxide to yield a product having enchanced immunogenic properties and reduced toxicity.
    Type: Grant
    Filed: February 13, 1981
    Date of Patent: December 21, 1982
    Inventor: Gijsberk T. Hoek
  • Monoclonal antibody to a human T cell antigen and methods of preparing same
    Patent number: 4364937
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: January 8, 1980
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
    Patent number: 4364934
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to a human thymocyte antigen and methods of preparing same
    Patent number: 4364933
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 70% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Method for treating hyperbilirubinemia
    Patent number: 4363801
    Abstract: Methods and preparations for treating hyperbilirubinemia utilizing chitosan salts as the active agent. A method of preparing the chitosan salts for oral administration in a liquid carrier is disclosed.
    Type: Grant
    Filed: February 9, 1981
    Date of Patent: December 14, 1982
    Assignee: The Texas A&M University System
    Inventor: Joseph J. Nagyvary
  • Monoclonal antibody to human T cells, and methods for preparing same
    Patent number: 4363799
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: March 20, 1979
    Date of Patent: December 14, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Cosmetic vehicle
    Patent number: 4362715
    Abstract: A combination of an acidic functional polymer and zeolite and/or amorphous alumino silicate provides a gel suitable as a cosmetic vehicle plus supplying functionality as well. The components combine easily to provide a creamy gel that is compounded with other ingredients to provide the complete cosmetic composition. The zeolite or amorphous alumino silicate is present in a sufficient quantity to provide functionality as well as the desired rheology. The combination can be used to compound astringent creams or lotions, make-up bases, facial masks, deodorant compositions, antiperspirants, anti-acne compositions, wrinkle smoothers or erasers, pore minimizers, and body lotions. An especially useful zeolite or amorphous alumino silicate is a material that contains aluminum as the cation.
    Type: Grant
    Filed: December 5, 1980
    Date of Patent: December 7, 1982
    Assignee: PQ Corporation
    Inventors: Sabbat J. Strianse, Howard S. Sherry, Elliot P. Hertzenberg
  • Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
    Patent number: 4361549
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells and cutaneous T lymphoma cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: April 26, 1979
    Date of Patent: November 30, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Aluminum ibuprofen pharmaceutical suspensions
    Patent number: 4361580
    Abstract: Aluminum ibuprofen pharmaceutical liquid suspensions having improved resistance to dissolution rate reduction upon storage containing aluminum ibuprofen, a suspending agent have a particle size below 50 microns, a water-soluble surface active agent, water, and preferably also from 5 to 30 grams of sucrose per 100 ml of suspension are disclosed, or its sweetening equivalent of glucose, fructose, sodium saccharin sodium cyclamate, or mixtures thereof.
    Type: Grant
    Filed: May 11, 1981
    Date of Patent: November 30, 1982
    Assignee: The Upjohn Manufacturing Company
    Inventors: Susanne M. Peck, Lois J. Larion, Englebert L. Rowe
  • Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
    Patent number: 4361550
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: November 30, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Diagnostic test composition for dental caries activity
    Patent number: 4359455
    Abstract: A test composition for evaluating dental caries activity, which comprise a specific amount of a saccharide (e.g. sucrose, glucose and fructose) and a pH indicator (e.g. resazurin, lacmoid, methyl red and alizarin) in water or an aqueous alcohol solution, said composition being regulated to a pH range of 6.5 to 7.0 with an alkali (e.g. sodium hydroxide) and an acid (e.g. acetic acid, tartaric acid or lactic acid). By using this test composition, a test for evaluation dental caries activity can be done within a very short period of time (e.g. about 30 minutes) by any person without requesting any specific training.
    Type: Grant
    Filed: October 30, 1979
    Date of Patent: November 16, 1982
    Assignee: Sunstar Hamigaki Kabushiki Kaisha
    Inventors: Masakazu Nakamura, Kikuko Hamato
  • Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
    Patent number: 4359457
    Abstract: A tumor suppressive composition active against lymphoma consisting of an injection of hybrid protein anti Thy 1.2 monoclonal antibody-ricin and hyperosmotic lactose. The inoculation i.v. of murine tissues in vivo by lymphoma is made at -20 to -25 days and the tumor suppressant composition is used i.v. at Day 1 in an amount of 1-3 .mu.g of anti Thy monoclonal antibody-ricin together with sufficient hyperosmotic lactose to raise the lactose level to 20-30 mM. The broad purpose of this invention is to modify the receptor specificity of a potent toxin such as ricin by coupling it with a monoclonal antibody directed at a specific tumor or differentiation antigen. The object here is to use the reagent to selectively kill tumor cells without affecting normal cells.
    Type: Grant
    Filed: September 30, 1980
    Date of Patent: November 16, 1982
    Inventors: David M. Neville, Jr., Richard J. Youle
  • Substrate for immunoassay and means of preparing same
    Patent number: 4357311
    Abstract: A method is disclosed for preparing an activated microporous substrate to which antibody may be covalently bonded through trichloro-triazine to yield an activated substrate which is very useful for many immunochemical reactions utilizing a flow-through procedure.
    Type: Grant
    Filed: October 3, 1980
    Date of Patent: November 2, 1982
    Assignee: Warner-Lambert Company
    Inventor: Ernest G. Schutt
  • Recovering purified antibodies from egg yolk
    Patent number: 4357272
    Abstract: Immunological preparations are prepared by immunizing hens with an antigen, preferably to a stage of hyperimmunization. The eggs of the immunized hens are collected, the yolk is separated from the eggs, followed by separation of the lipid content of the yolk. The antibodies in the egg yolk are then rendered indispersable with the aid of a water-soluble linear filamentary non-charged polymer precipitant such as PEG and the indispersable antibodies are recovered. This precipitation of antibodies is preferably preceded by a precipitation of caseinaceous proteins at lower polymer concentrations.The immunological preparations are useful for diagnostic purposes and in appropriate cases also for the treatment of pathological conditions.
    Type: Grant
    Filed: March 15, 1979
    Date of Patent: November 2, 1982
    Assignee: The South African Inventions Development Corporation
    Inventor: Alfred Polson
  • Hepatitis A testing and growth in tree shrew as animal model
    Patent number: 4355019
    Abstract: Tree shrews (Tupaia belangeri) are used as an animal model to test the inactivation of vaccines, the harmlessness of blood products and the effectiveness of chemotherapeutic agents and disinfectants against viral hepatitis. The antibody determinations are performed at specific intervals for a period of 150 days in the case of viral hepatitis type A and 60 days in the case of viral hepatitis type B.
    Type: Grant
    Filed: August 29, 1980
    Date of Patent: October 19, 1982
    Assignee: Battelle-Institut e.V.
    Inventors: Peter Lorenz, Anita Schwaier
  • Diagnosis of tumors or bacterial infections having .beta.-glucuronidase activity
    Patent number: 4351823
    Abstract: A method of diagnosing the presence of tumors having .beta.-glucuronidase activity comprises administering a glucuronide which differs in color or color intensity from the aglycone thereof to a patient. The preferred glucuronide is phenolphthalein glucuronide. The urine is then collecting for a twenty four hour period and the amount of phenolphthalein glucuronides present in the urine is determined. If substantially all of the phenolphthalein glucuronide is expelled then it is apparent that the body has no tumors or bacterial infections exhibiting .beta.-glucuronidase activity. If however substantial amounts of phenolphthalein is retained, then this is an indication of the presence of tumors having .beta.-glucuronidase activity or a bacterial infection having .beta.-glucuronidase activity.
    Type: Grant
    Filed: July 18, 1980
    Date of Patent: September 28, 1982
    Assignees: Adolf W. Schwimmer, Irwin S. Schwartz, David Rubin
    Inventor: David Rubin
  • Polystyrene latex reagents, methods of preparation, and use in immunological procedures
    Patent number: 4351824
    Abstract: Methods of making and using a stable diagnostic reagent for use in serological testing procedures, and in particular, non-auto-agglutinating polystyrene latex particles with surfaces containing a protein, substantially methylated serum albumin, and a bound, negatively-charged polymeric compound. The particles may be sensitized with a number of negatively-charged compounds, including proteins, polysaccharides and various cell nuclear components. When the coated latex particles are adsorbed with native deoxyribonucleic acid, the resultant immunological reagent can be used to detect certain autoimmune diseases, particularly serum lupus erythematosus.
    Type: Grant
    Filed: February 5, 1981
    Date of Patent: September 28, 1982
    Assignee: ICL Scientific
    Inventor: Harris I. Lehrer